New drug AG-236 gets first human safety check
NCT ID NCT07075640
First seen Jun 27, 2026 · Last updated Jul 31, 2026 · Updated 2 times
Summary
This early-stage study is testing a single injection of a new drug called AG-236 in 24 healthy adults aged 18 to 55. The main goal is to see if it is safe and how the body processes it. No treatment for any disease is being tested here.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY PARTICIPANTS are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Fortrea Clinical Research Unit Inc.
Madison, Wisconsin, 53704, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a common antifungal change how an experimental drug acts?
- Can a new injection help tackle obesity? a safety trial begins
- Will a new pill formula absorb the same? a trial puts it to the test
- Can a new drug tame Alzheimer's? early trial aims to find out
- Could sitting too much alter your nervous system?
- Could a cancer drug alter Metformin's effects? a trial investigates